Latest Certolizumab pegol Stories
EXTON, Pa., Nov. 3, 2010 /PRNewswire/ -- Bio-Trends is pleased to announce the publication of a new syndicated report, TreatmentTrendsÂ®: Rheumatoid Arthritis Q3 2010. This report covers the use of biologics for the treatment of rheumatoid arthritis (RA).
ATLANTA, Oct. 15 /PRNewswire/ -- Studies and analyses of the Crohn's disease (CD) treatment CimziaÂ® (certolizumab pegol) will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology, taking place in San Antonio from October 15 - 20.
BURLINGTON, Mass., Oct.
BURLINGTON, Mass., Sept.
Biological agents may play an important role in maintaining remission in Crohn's disease, according to two new studies in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.
ATLANTA, June 16 /PRNewswire-FirstCall/ -- UCB today announced new CimziaÂ® (certolizumab pegol) data demonstrating rapid and sustained improvements in managing moderate to severe rheumatoid arthritis (RA) symptoms and pain for patients, as well as results of a survey showing the impact of RA pain on the daily lives of women, focusing on productivity and relationships, during the 2010 European League Against Rheumatism (EULAR) annual congress in Rome, Italy, June 16-19. "Insights from these...
ATLANTA, May 2 /PRNewswire/ -- UCB announced today results of an open-label extension study, PRECiSE 4 (P4), of CimziaÂ® (certolizumab pegol; CZP) demonstrating that Cimzia provides sustained efficacy over four years in moderate to severe Crohn's Disease patients regardless of whether patients were previously treated with infliximab (IFX) or infliximab-naive.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.